Rubicon Organics: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (ROMJ)
Rubicon Organics is now ranked among the top 10 undervalued stocks in the Healthcare sector on the TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below). The healthcare sector contains companies in biotechnology, pharmaceuticals, hospitals, home and long-term care as well as related medical equipment manufacturers and suppliers.
All data provided as-at market close November 27, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Rubicon Organics Rubicon Organics Inc is engaged in the cultivation of cannabis. The segments of the company are Canadian development of facilities for the production and sale of cannabis, Corporate costs, and Discontinued operations related to the United States. Rubicon Organics is listed under ROMJ on the TSX Venture Exchange.
| Symbol | Name | Close Price | Shares Outstanding | P/E | P/B | Cash per Share | Net Cash per Share |
|---|---|---|---|---|---|---|---|
| VXL-X | Vaxil Bio | 0.01 | 0 | 0 | 0 | 0 | 0 |
| MNOW-X | Mednow | 0.27 | 0 | 0 | 0 | 0 | 0 |
| JUMP-X | Leveljump Healthcare | 0.07 | 0 | 0 | 0 | 0 | 0 |
| IBO-X | Universal Ibogaine | 0.03 | 0 | 0 | 0 | 0 | 0 |
| NLTA-X | Enlighta | 0.07 | 0 | 0 | 0 | 0 | 0 |
| KNE-X | Kane Biotech | 0.08 | 0 | 0 | 0 | 0 | 0 |
| NLH-X | Nova Leap Health | 0.27 | 0 | 0 | 0 | 0 | 0 |
| ACST-X | Acasti Pharma | 0.56 | 0 | 0 | 0 | 0 | 0 |
| THNK-X | Think Research | 0.32 | 0 | 0 | 0 | 0 | 0 |
| ROMJ-X | Rubicon Organics | 0.64 | 0 | 0 | 0 | 0 | 0 |
More about Rubicon Organics
Stocks in this category are held primarily for capital appreciation.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
